Development of a novel therapeutic strategy for canine inflammatory bowel disease using selective lymphocyte induction

2015 Fiscal Year Final Research Report

• Project/Area Number: 26660237
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Veterinary medical science
• Research Institution: The University of Tokyo
• Principal Investigator: Koshino Yuko (GOTO Yuko) 東京大学, 農学生命科学研究科, 特任准教授 (80436518)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: ラパマイシン / 犬 / Treg / リンパ球 / 炎症性腸疾患

Outline of Final Research Achievements

The aim of this study was; 1. To evaluate the effect of Rapamycin in canine Inflammatory bowel disease as a novel therapeutic drug; 2. To investigate the involvement of Treg and Th17 cells in clinical pahology of canine inflammatory bowel disease.
We added Rapamycin, IL-2 and TGFb to ConA-stimulated canine peripheral lymphocytes in various combination. However, compared to lymphocytes cultured with ConA alone, neither of the combination achieved significant increase in Treg cell percentage nor numbers. It might be necessary to evaluate culture condition other than ConA stimulation-based method.

Free Research Field

獣医内科学